

Drug Policy:

Jaypirca™ (pirtobrutinib)

POLICY NUMBER UM ONC_1476	SUBJECT Jaypirca™ (pirtobrutinib)		DEPT/PROGRAM UM Dept	PAGE 1 of 3
DATES COMMITTEE REVIEWED 03/08/23, 12/13/23, 12/12/24	APPROVAL DATE December 12, 2024	EFFECTIVE DATE December 27, 2024	COMMITTEE APPROVAL DATES 03/08/23, 12/13/23, 12/12/24	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Evolut Specialty Services Clinical Guideline Review Committee		
NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT		
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

Evolut clinical guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolut uses clinical guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolut Clinical Guidelines. A list of codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolut reserves the right to review and update this clinical guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their plan customer service representative for specific coverage information.

I. PURPOSE

To define and describe the accepted indications for Jaypirca (pirtobrutinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolut is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolut may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. Continuation requests for a not-approvable medication shall be exempt from this Evolut policy provided:

1. The requested medication was used within the last year, **AND**

2. The member has not experienced disease progression and/or no intolerance to the requested medication, AND
3. Additional medication(s) are not being added to the continuation request.

B. Mantle Cell Lymphoma (MCL)

1. Jaypirca (pirtobrutinib) may be used as monotherapy in members with relapsed/refractory Mantle Cell Lymphoma who were previously treated with 2 or more prior lines of systemic therapy, including chemoimmunotherapy (e.g., RCHOP, bendamustine + rituximab/rituximab biosimilars) AND a Bruton Tyrosine Kinase inhibitor (e.g., acalabrutinib, ibrutinib, zanubrutinib).

C. Chronic Lymphocytic Lymphoma or Small Lymphocytic Lymphoma (CLL/SLL)

1. Jaypirca (pirtobrutinib) may be used as monotherapy in members with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor (e.g., zanubrutinib, acalabrutinib, ibrutinib) and a BCL-2 inhibitor (e.g., venetoclax).

III. EXCLUSION CRITERIA

- A. Disease progression on treatment with Jaypirca (pirtobrutinib).
- B. Dosing exceeds single dose limit of Jaypirca (pirtobrutinib) 200 mg.
- C. Treatment with Jaypirca (pirtobrutinib) exceeds the maximum limit of 30 (50 mg) and 60 (100 mg) tablets/month.
- D. Investigational use of Jaypirca (pirtobrutinib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 4. Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. CODING INFORMATION

HCPCS Code	Description
J9399	pirtobrutinib

V. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

VI. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VII. ATTACHMENTS

- A. None

VIII. REFERENCES

- A. Mato AR, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6;397(10277):892-901. DOI: [https://doi.org/10.1016/S0140-6736\(21\)00224-5](https://doi.org/10.1016/S0140-6736(21)00224-5)
- B. Wang E, et al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med. 2022 Feb 24;386(8):735-743.
- C. Jaypirca (prescribing information). Eli Lilly and Company Indianapolis, IN 2024.
- D. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs Bethesda, MD 2024.
- E. Clinical Pharmacology Elsevier Gold Standard 2024.
- F. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2024.
- G. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2024.
- H. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20;32(12):1277-80.
- I. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.